A randomized, double-blind, placebo-controlled trial of anti-IgE for chronic rhinosinusitis.
Pinto
J M
JM
Department of Surgery, Section of Otolaryngology-Head and Neck Surgery, The University of Chicago, Chicago, IL 60637, USA.
Mehta
N
N
DiTineo
M
M
Wang
J
J
Baroody
F M
FM
Naclerio
R M
RM
D000328:Adult; D018926:Anti-Allergic Agents / Q000627:therapeutic use*; D000888:Antibodies, Anti-Idiotypic; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D002908:Chronic Disease; D004311:Double-Blind Method; D005260:Female; D006305:Health Status Indicators; D006801:Humans; D007073:Immunoglobulin E / Q000502:physiology; D008297:Male; D008875:Middle Aged; D000069444:Omalizumab; D011788:Quality of Life; D012220:Rhinitis / Q000188:drug therapy* / Q000503:physiopathology; D012852:Sinusitis / Q000188:drug therapy* / Q000503:physiopathology; D016896:Treatment Outcome
D018926:Anti-Allergic Agents; D000888:Antibodies, Anti-Idiotypic; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000069444:Omalizumab; D007073:Immunoglobulin E